Cureus,
Journal Year:
2023,
Volume and Issue:
unknown
Published: Aug. 4, 2023
A
39-year-old
Japanese
male
patient
presented
with
a
chief
complaint
of
gross
hematuria
persistent
for
two
months.
However,
no
relevant
findings
in
the
patient’s
medical
and
family
history
were
observed.
He
was
diagnosed
muscle-invasive
bladder
cancer,
clinical
stage
T2bN0M0.
After
four
courses
neoadjuvant
chemotherapy
gemcitabine
cisplatin,
tumor
size
reduced
by
approximately
30%.
The
underwent
robot-assisted
radical
cystectomy
standard
lymph
node
dissection
followed
intracorporeal
ileal
conduit
reconstruction.
Histologically,
as
high-grade
urothelial
carcinoma
invading
fatty
tissue
surrounding
metastasizing
to
nodes,
pathological
ypT3aypN2M0.
Four
months
after
surgery,
multiple
metastases
detected,
treatment
pembrolizumab
initiated
immediately.
did
not
respond
pembrolizumab.
Therefore,
third-line
enfortumab
vedotin
(EV)
initiated.
Thereafter,
metastatic
lesion
shrank
quickly,
lesions
almost
disappeared
EV
administration.
Although
new
observed
at
other
sites,
there
has
been
regrowth
date.
EV-related
adverse
events
during
follow-up.
Eighteen
remains
alive
metastases.
sequence
should
be
considered
maximize
therapeutic
effect
EV,
and,
consequently,
administering
early
possible
may
important.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(12), P. 2246 - 2246
Published: June 18, 2024
Immune
checkpoint
inhibitor
(ICI)
therapies
have
been
established
as
the
standard-of-care
in
various
uro-oncological
cancers.
Immune-related
adverse
events
(irAEs)
are
frequent,
but
their
degree
rarely
leads
to
discontinuation
of
immunotherapies.
Unplanned
permanent
treatment
may
negatively
impact
outcomes
patients,
there
emerging
data
about
a
positive
correlation
between
emergence
severe
irAEs
and
therapeutic
cancer
responses.
In
this
study,
retrospective
analysis
patients
treated
for
urothelial
carcinoma
(UC)
with
ICI-based
immunotherapy
was
conducted.
were
classified
according
Common
Terminology
Criteria
Adverse
Events
(CTCAEs)
radiological
responses
Response
Evaluation
Solid
Tumors
(RECISTs).
Out
108
metastatic
that
underwent
immunotherapy,
11
experienced
irAE
required
ICI
therapy.
The
most
frequent
leading
hepatitis
(n
=
4),
pneumonitis
2),
gastritis
or
colitis
2).
Prior
(R1),
best
response
complete
remission
(CR)
three
partial
(PR)
six,
stable
disease
(SD)
wo
patients.
After
therapy
(R2),
CR
PR
three,
SD
two
Following
discontinuation,
majority
these
showed
sustained
response,
despite
not
receiving
any
cancer-specific
treatment.
median
time
after
26.0
(5.2–55.8)
months.
We
propose
accurate
counseling
close
follow-ups
following
due
irAEs,
can
be
durable
deep,
many
do
require
immediate
subsequent
therapies,
even
cancer.
More
find
predictors
length
appropriately
counsel
International Journal of Urology,
Journal Year:
2024,
Volume and Issue:
unknown
Published: Nov. 22, 2024
Abstract
Background
While
the
occurrence
of
immune‐related
adverse
events
has
been
recognized
as
a
prognostic
marker
in
patients
receiving
immune
checkpoint
inhibitors,
significance
treatment‐related
(trAEs)
undergoing
antibody–drug
conjugates
such
enfortumab
vedotin
(EV)
is
controversial.
Methods
We
reviewed
106
with
advanced
urothelial
carcinoma
who
were
treated
EV
therapy
at
10
institutions
between
2021
and
2023.
Associations
clinical
parameters
overall
survival
progression‐free
assessed
using
Cox
proportional
hazards
model.
For
assessment
trAEs,
landmark
analysis
was
conducted
to
minimize
immortal
time
bias.
Results
Of
patients,
55
(51.9%)
experienced
disease
progression
44
(41.5%)
died
during
follow‐up
period.
Any
grade
≥3
trAEs
occurred
94
(88.7%)
respectively.
Common
included
skin
disorders
(74.5%),
gastrointestinal
(62.3%),
fatigue
(50.0%),
peripheral
neuropathy
(36.8%),
hematological
(37.7%).
One
patient
interstitial
pneumonia
(grade
5).
According
88
survived
for
2
months
or
more,
significantly
associated
longer
survival.
Furthermore,
when
classified
into
“physical
trAEs”
“laboratory
disorders,
former
while
latter
shorter
Conclusions
Physical,
but
not
laboratory,
are
favorable
outcomes
carcinoma.
Both
managing
utilizing
them
markers
key
points
use
EV.
Frontiers in Pharmacology,
Journal Year:
2024,
Volume and Issue:
15
Published: Dec. 6, 2024
Introduction
Enfortumab
vedotin
(EV)
and
Erdafitinib
are
effective
therapeutic
drugs
for
bladder
cancer
patients
following
post-chemotherapy
immunotherapy.
This
study
assessed
adverse
drug
reactions
(ADRs)
from
both
drugs,
comparing
their
safety
profiles
to
guide
clinical
use.
Methods
A
retrospective
descriptive
analysis
was
conducted
on
ADR
reports
EV
the
World
Health
Organization
(WHO)-VigiAccess
database.
Data
patient
demographics,
system
organ
classes
(SOCs),
global
regions,
symptoms,
ADRs
frequencies
were
analyzed
compared.
Results
As
of
2024,
3,438
identified
(2,257
1,181
Erdafitinib).
The
number
reaction
is
significantly
higher
than
that
Erdafitinib.
Among
them,
SOC
with
most
signals
gastrointestinal
disorders,
top
five
being
nausea,
dry
mouth,
abdominal
pain,
diarrhea.
reported
events
(AEs)
as
follows:
skin
subcutaneous
tissue
disorders
(20.70%),
general
administration
site
conditions
(14.23%),
nervous
(11.12%),
(7.78%),
metabolism
nutrition
(6.47%).
In
contrast,
AEs
are:
(25.36%),
(10.94%),
(10.19%),
eye
(9.21%),
injury
poisoning
procedural
complications
(7.31%).
Conclusion
Our
compared
potential
novel
between
Erdafitinib,
providing
key
insights
into
highlighting
need
personalized
treatment
strategies
based
individual
risk
factors.
Cureus,
Journal Year:
2023,
Volume and Issue:
unknown
Published: Aug. 4, 2023
A
39-year-old
Japanese
male
patient
presented
with
a
chief
complaint
of
gross
hematuria
persistent
for
two
months.
However,
no
relevant
findings
in
the
patient’s
medical
and
family
history
were
observed.
He
was
diagnosed
muscle-invasive
bladder
cancer,
clinical
stage
T2bN0M0.
After
four
courses
neoadjuvant
chemotherapy
gemcitabine
cisplatin,
tumor
size
reduced
by
approximately
30%.
The
underwent
robot-assisted
radical
cystectomy
standard
lymph
node
dissection
followed
intracorporeal
ileal
conduit
reconstruction.
Histologically,
as
high-grade
urothelial
carcinoma
invading
fatty
tissue
surrounding
metastasizing
to
nodes,
pathological
ypT3aypN2M0.
Four
months
after
surgery,
multiple
metastases
detected,
treatment
pembrolizumab
initiated
immediately.
did
not
respond
pembrolizumab.
Therefore,
third-line
enfortumab
vedotin
(EV)
initiated.
Thereafter,
metastatic
lesion
shrank
quickly,
lesions
almost
disappeared
EV
administration.
Although
new
observed
at
other
sites,
there
has
been
regrowth
date.
EV-related
adverse
events
during
follow-up.
Eighteen
remains
alive
metastases.
sequence
should
be
considered
maximize
therapeutic
effect
EV,
and,
consequently,
administering
early
possible
may
important.
